Editas Medicine Inc [EDIT] stock is trading at $5.54, up 1.28%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EDIT shares have gain 20.70% over the last week, with a monthly amount glided 2.03%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Editas Medicine Inc [NASDAQ: EDIT] stock has seen the most recent analyst activity on May 09, 2024, when Morgan Stanley upgraded its rating to a Equal-Weight but kept the price target unchanged to $7 for it. Previously, Citigroup upgraded its rating to Buy on October 24, 2023, and kept the price target unchanged to $11. On October 18, 2023, upgrade upgraded it’s rating to Neutral but maintained its price target of $8 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral. Stifel upgraded its rating to a Buy and raised its price target to $17 on September 29, 2023. Raymond James upgraded its rating to Outperform for this stock on June 12, 2023, but kept the price target unchanged to $17. In a note dated February 01, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $15 on this stock.
Editas Medicine Inc [EDIT] stock has fluctuated between $4.45 and $11.69 over the past year. Currently, Wall Street analysts expect the stock to reach $19.5 within the next 12 months. Editas Medicine Inc [NASDAQ: EDIT] shares were valued at $5.54 at the most recent close of the market. An investor can expect a potential return of 251.99% based on the average EDIT price forecast.
Analyzing the EDIT fundamentals
Editas Medicine Inc [NASDAQ:EDIT] reported sales of 69.41M for the trailing twelve months, which represents a drop of -88.48%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -2.59%, Pretax Profit Margin comes in at -2.39%, and Net Profit Margin reading is -2.39%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.47 and Total Capital is -0.48. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.37 points at the first support level, and at 5.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.74, and for the 2nd resistance point, it is at 5.93.
Ratios To Look Out For
For context, Editas Medicine Inc’s Current Ratio is 4.60. As well, the Quick Ratio is 4.60, while the Cash Ratio is 1.04. Considering the valuation of this stock, the price to sales ratio is 6.56, the price to book ratio is 1.55.
Transactions by insiders
Recent insider trading involved O’Neill Gilmore Neil, CEO, that happened on Jun 04 ’24 when 12191.0 shares were sold. EVP, CHIEF MEDICAL OFFICER, Mei Baisong completed a deal on Jun 04 ’24 to sell 511.0 shares. Meanwhile, EVP, CHIEF FINANCIAL OFFICER Lucera Erick sold 22337.0 shares on May 20 ’24.
